These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22582547)

  • 1. The association between dyslipidaemia and types of antipsychotic medications among patients with chronic schizophrenia.
    Ruzanna ZZ; Ong LY; Cheah YC; Fairuz A; Marhani M
    Med J Malaysia; 2012 Feb; 67(1):39-44. PubMed ID: 22582547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy.
    Huang TL; Lu CY
    Chang Gung Med J; 2007; 30(1):26-32. PubMed ID: 17477026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
    Hanssens L; De Hert M; Kalnicka D; van Winkel R; Wampers M; Van Eyck D; Scheen A; Peuskens J
    Int Clin Psychopharmacol; 2007 Jan; 22(1):43-9. PubMed ID: 17159459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Schizophrenia, obesity and pharmacotherapy-associated weight gain].
    Carpiniello B; Corda E; Maccioni R; Pinna F
    Clin Ter; 2008; 159(5):299-306. PubMed ID: 18998030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications.
    Jerrell JM; McIntyre RS
    Hum Psychopharmacol; 2007 Aug; 22(6):361-4. PubMed ID: 17562519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid dose-dependent effect of clozapine on a schizophrenic patient's lipid profile.
    Chiang HL; Liu CC; Hwang TJ
    J Psychopharmacol; 2009 Jun; 23(4):465-7. PubMed ID: 18562410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey.
    Diatta T; Blazejewski S; Portier A; Lignot S; Quesnot A; Moore N; Fourrier-Réglat A
    Fundam Clin Pharmacol; 2007 Aug; 21(4):371-8. PubMed ID: 17635175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
    Watanabe A; Shibata I; Kato T
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of second generation antipsychotics on leptin and ghrelin.
    Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?
    Bushe C; Paton C
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):76-83. PubMed ID: 16280340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zonisamide-induced weight loss in schizophrenia: case series.
    Yang J; Lee MS; Joe SH; Jung IK; Kim SH
    Clin Neuropharmacol; 2010; 33(2):104-6. PubMed ID: 19935403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders.
    Chiang YL; Klainin-Yobas P; Ignacio J; Chng CM
    J Clin Nurs; 2011 Aug; 20(15-16):2172-82. PubMed ID: 21539628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes prevalence estimates in schizophrenia and risk factor assessment.
    Argo T; Carnahan R; Barnett M; Holman TL; Perry PJ
    Ann Clin Psychiatry; 2011 May; 23(2):117-24. PubMed ID: 21547272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.